Deng Junli, Tang Jie, Wang Guo, Zhu Yuan-Shan
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
Int J Environ Res Public Health. 2017 Mar 7;14(3):270. doi: 10.3390/ijerph14030270.
Whole genome transcriptomic analyses have identified numerous long non-coding RNA (lncRNA) transcripts that are increasingly implicated in cancer biology. LncRNAs are found to promote essential cancer cell functions such as proliferation, invasion, and metastasis, with the potential to serve as novel biomarkers of various cancers and to further reveal uncharacterized aspects of tumor biology. However, the biological and molecular mechanisms as well as the clinical applications of lncRNAs in diverse diseases are not completely understood, and remain to be fully explored. LncRNAs may be critical players and regulators in prostate cancer carcinogenesis and progression, and could serve as potential biomarkers for prostate cancer. This review focuses on lncRNA biomarkers that are already available for clinical use and provides an overview of lncRNA biomarkers that are under investigation for clinical development in prostate cancer.
全基因组转录组分析已鉴定出众多长链非编码RNA（lncRNA）转录本，它们在癌症生物学中的作用日益受到关注。lncRNAs被发现可促进癌细胞的增殖、侵袭和转移等基本功能，有望作为多种癌症的新型生物标志物，并进一步揭示肿瘤生物学中尚未明确的方面。然而，lncRNAs在多种疾病中的生物学和分子机制以及临床应用尚未完全明确，仍有待充分探索。lncRNAs可能是前列腺癌发生和进展的关键参与者和调节因子，并可作为前列腺癌的潜在生物标志物。本综述重点关注已可用于临床的lncRNA生物标志物，并概述了正在前列腺癌临床开发中研究的lncRNA生物标志物。
